Brief: Philochem Announces Licensing Of Oncoacp3, To Rayzebio, A Bristol-Myers Squibb Company, For A Potential Value Of Up To $1.35Bn Plus Royalties

Philogen

10/06/2025 23:02

June 10 (Reuters) - Philogen SpA PHIL.MI:

PHILOCHEM AG ANNOUNCES THE LICENSING OF WORLDWIDE RIGHTS TO ONCOACP3, A NOVEL RADIOPHARMACEUTICAL THERAPEUTIC AND DIAGNOSTIC AGENT TARGETING PROSTATE CANCER, TO RAYZEBIO, A BRISTOL-MYERS SQUIBB COMPANY, FOR A POTENTIAL VALUE OF UP TO $1.35BN PLUS ROYALTIES

PHILOGEN SPA - CONSIDERATION COMPOSED OF A $350M UP-FRONT PAYMENT

PHILOGEN SPA- CO WILL RECEIVE MID-SINGLE TO LOW DOUBLE-DIGIT ROYALTIES PAYABLE ON GLOBAL NET SALES OF THERAPEUTIC AND DIAGNOSTIC AGENTS OF ONCOACP3

PHILOGEN SPA - CONSIDERATION COMPOSED OF UP TO $1.0BN IN DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES

Source text: ID:nGNEHhRwj

Further company coverage: PHIL.MI

 ((reuters.briefs@thomsonreuters.com;))